Approach to vaccination in systemic lupus erythematosus on biological treatment

YILDIRIM R., Oliveira T., Isenberg D. A.

ANNALS OF THE RHEUMATIC DISEASES, vol.82, no.9, pp.1123-1129, 2023 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Review
  • Volume: 82 Issue: 9
  • Publication Date: 2023
  • Doi Number: 10.1136/ard-2023-224071
  • Journal Name: ANNALS OF THE RHEUMATIC DISEASES
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, CAB Abstracts, CINAHL, EMBASE, MEDLINE, Veterinary Science Database
  • Page Numbers: pp.1123-1129
  • Keywords: Lupus Erythematosus, Systemic, Rituximab, Immune System Diseases, INFLUENZA VACCINATION, RHEUMATOID-ARTHRITIS, HERPES-ZOSTER, PNEUMOCOCCAL VACCINATION, POLYSACCHARIDE VACCINE, ANTIBODY-RESPONSES, IMMUNOGENICITY, SAFETY, IMMUNIZATION, AUTOIMMUNE
  • Eskisehir Osmangazi University Affiliated: Yes

Abstract

In recent years, treat-to-target strategy and early intervention strategies with immunosuppressive agents have attempted to improve the prognosis and outcome in patients with autoimmune inflammatory rheumatic diseases. However, infectious complications due to side effects of medication remain a major concern in routine practice. In this regard, vaccine immunity and vaccination programmes are of the utmost importance in patients with systemic lupus erythematosus (SLE) in terms of morbidity and mortality. Encouragingly, research investigations have increased exponentially, both in monitoring the vaccines efficacy, and in determining the immune response while patients are on immunosuppression., However, in this biological era in rheumatology, relatively little data have been published investigating these parameters in those receiving biological agents, therefore, no definitive consensus about a vaccination policy for patients with SLE is currently available. In this review, we aim to address what is established about vaccinating patients with SLE on biological agents and discuss potential problems.